Loading...

KALV KALVISTA PHARMACEUTICALS INC Company Mergers 8-K Filing

KLVS

KLV

KALVISTA PHARMACEUTICALS INC

(KALV)

2025 8-K

Show Summary

Show Summary

License Agreement

Fiscal Year Change

Financial Results

Management Change

Financial Results

Board Appointment

Revenue Rights Sale

Annual Meeting Results

Management Changes

Financial Results

Lease Agreement

Financial Results

Financial Results

Public Offering

Termination of Sales Agreement

Clinical Data Announcement

Financial Results

Amendment to Certificate of...

Financial Results

Amended Employment Agreement

Financial Results

Appointment of President

External Links:

On April 8, 2025, KalVista Pharmaceuticals entered a License Agreement with Kaken Pharmaceutical for commercialization rights in Japan for sebetralstat, receiving an upfront payment of $11 million and potential additional payments of up to $13 million based on milestones.

AI Assistant

KALVISTA PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.